Conference abstract · 23 Jun 2025
Research articlePublished 2017
Durability of Boosted Atazanavir (ATV) or Darunavir (DRV) Plus Maraviroc (MVC) Dual rescue Therapy in Poorly Adherent Subjects in View of Long-Acting Drugs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In poorly adherent HIV-infected subjects strategic approaches may avoid resistance to long-acting compounds. This study means to assess the safety of a strategy which was being carried out in our Division in several nonadherent subjects with general satisfaction. All subjects who had been switched to boosted protease inhibitors plus maraviroc for treatment failure between June 2014, and April 2015, were retrospectively evaluated. Eighteen were taking darunavir/ritonavir and 26 atazanavir/ritonavir plus maraviroc 300 mg once daily. All had a follow-up of 104 weeks and 27 exceeded 156 weeks. One patient, who was INSTI-experienced and still had >500 HIV-1 RNA copies/mL at week 60, switched to dolutegravir plus darunavir/ritonavir and rapidly failed, selecting for INSTI cross resistance-associated mutations (97A, 140S and 148H). At week 96 and 140, 81.8% and 85.2% had <50 HIV-1 RNA copies/mL, respectively. No one else selected resistance mutations nor switched co-receptor tropism. All remain eligible for long-acting therapy.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Amedeo F Capetti”
- BylineArticles whose byline prints “Noemi Astuti”
- BylineArticles whose byline prints “Simona Landonio”
- BylineArticles whose byline prints “Fosca P Niero”
- BylineArticles whose byline prints “Stefania Vimercati”
- BylineArticles whose byline prints “Gianfranco Dedivitiis”
- BylineArticles whose byline prints “Giuliano Rizzardini”
